Comparative Pharmacology
Head-to-head clinical analysis: MELPHALAN HYDROCHLORIDE versus TEPYLUTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELPHALAN HYDROCHLORIDE versus TEPYLUTE.
MELPHALAN HYDROCHLORIDE vs TEPYLUTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Melphalan is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription. It is cell cycle phase-nonspecific.
Progestin that transforms endometrium from proliferative to secretory phase, inhibits gonadotropin secretion, and increases cervical mucus viscosity.
16 mg/m² intravenously over 15-20 minutes every 2 weeks for 4 doses, then every 4 weeks
100 mg orally once daily
None Documented
None Documented
1.5-2.5 h (terminal) in normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is 4-6 hours in healthy adults; prolonged to 10-15 hours in severe renal impairment.
Renal: 10-30% unchanged; fecal: 20-30% as metabolites; biliary: minor.
Primarily renal (70-80% unchanged) and fecal (15-20% as metabolites).
Category D/X
Category C
Alkylating Agent
Alkylating Agent